Prenuvo Welcomes Jill Woodworth, Former Peloton CFO, As Chief Financial Officer
Woodworth is best known for her role as Chief Financial Officer at Peloton, where she helped scale the company from a late-stage startup into a publicly traded business with more than $4 billion in annual revenue at the time. She played a critical role in preparing the company for its IPO, navigating pandemic-era demand surges, and building operational infrastructure to support massive consumer adoption. Prior to Peloton, she spent over two decades as a Managing Director at J.P. Morgan and as an Executive Director at Morgan Stanley, advising Fortune 500 companies in the consumer and retail sectors on IPOs, M&A, and capital strategy. She most recently served as CFO at Alation, a data intelligence platform backed by top-tier investors.
'What drew me to Prenuvo is the same thing that drew me to Peloton years ago, the opportunity to change lives at scale,' said Jill Woodworth. 'After experiencing a scan myself, I realized how powerful it is to truly see what's happening inside your body. The more I learned, the clearer it became that no one else in this space is approaching this like Prenuvo. I believe Prenuvo and proactive healthcare can become as ubiquitous and essential as fitness and wellness movements have become in the past decade. I'm excited to help build a future where taking control of your health is a natural, expected part of life for everyone."
'Jill brings a rare combination of financial acumen and a deep understanding of consumer-driven health,' said Andrew Lacy, Founder and CEO of Prenuvo Inc. 'She's helped build one of the most recognized brands of the last decade, and her leadership will be essential as we scale globally and continue making proactive health more accessible.'
Prenuvo has quickly emerged as a category leader in proactive health and is now seeing record scan volumes month over month, driven by rising demand for early health insights across a broad range of consumer patient populations. Earlier this year, the company announced a historic milestone of 100,000 scans and net profitability. Since then, Prenuvo has surpassed 130,000 scans and introduced its Enhanced Scan, which combines whole-body imaging, advanced neuro screening, and blood diagnostics. In locations where it's available, the Enhanced Scan already accounts for a quarter of business, underscoring a growing demand for a single, trusted destination where patients can get a comprehensive view of their health without the complexity of piecing together multiple tests or providers. With 15 more locations set to launch - including the company's first sites in Europe and Australia - Prenuvo is scaling quickly to meet growing demand.
Prenuvo integrates MRI technology, its proprietary scanning protocols, AI tools and in-house R&D, and clinical reporting into a single, unified experience, enabling tighter quality control and a more seamless path from scan to diagnosis. The Prenuvo Medical Group brings together 150+ healthcare practitioners, including the world's largest private radiology team dedicated entirely to proactive whole body MRI screening, with over 100 board-certified radiologists on staff.
About Prenuvo
Prenuvo makes MRI scanning for early detection of many types of cancer and many other diseases seamless and more widely accessible. Combining cutting-edge analysis technology with radiation-free and non-invasive full-body scans, Prenuvo's patient-centric design is optimized to assess the body holistically and in under 60 minutes, compared with the several hours it would take to achieve this level of insight from conventional MRI scans.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 hours ago
- Business Insider
Would you pay $2,500 a year to scan your entire body for hidden diseases?
Doctors have been arguing over the utility of preventive full-body MRI scans for decades. In 2004, it became a central plot point on an episode of the TV show "Scrubs." "I am considering offering full-body scans here at Sacred Heart. What do you think?" Dr. Bob Kelso, chief of medicine at the hospital in fictional San DiFrangeles, asks. "I think showing perfectly healthy people every harmless imperfection in their body just to scare them into taking invasive and often pointless tests is an unholy sin," Dr. Perry Cox responds, echoing a sentiment many real doctors have toward high-end preventive scans. It's been more than 20 years since that Scrubs episode first aired, and yet real doctors are no closer to settling their big debate about full-body MRIs. Preventive full-body MRIs are now used in high-end longevity clinics and are available through a growing suite of direct-to-consumer offerings. Prices range from $2,500 or more for a one-hour scan to new AI-assisted offerings that cost $500 and only take about 20 minutes. Stars and longevity fiends, including Kim Kardashian, tout these scans on social media, and everyday patients share real success stories, gripping testimonials of lifesaving insights they've gleaned from scanning their entire bodies for signs of danger. Genetic sequencing pioneer Craig Venter previously told Business Insider that he diagnosed his own prostate cancer "that was about to metastasize" with a high-end MRI "after being told by the best medical system that I didn't have prostate cancer." Full-body MRIs can detect cancer early. But they can also have you parting with thousands of dollars, scheduling numerous follow up appointments to chase little dots on your scans, and in the end revealing nothing. A full-body MRI is like a security camera for your innards The promise of a full-body MRI is that it can uncover dangerous things happening inside you that aren't bad enough — yet — to get picked up on other tests. Danielle Hoeg is a perfect example of how this can work. A non-smoker in her early 40s and mom of three, she told Business Insider she decided to do a Prenuvo scan after some "wonky" blood work was taken at her doctor's office, which suggested something might be wrong. She signed up for a $2,500 Prenuvo scan (not covered by insurance), which took about an hour. The scan highlighted a few things: some moderate spinal degeneration and a lingering sinus infection. It also flagged a "minor" white cloud on her lung, an "indeterminate lesion" that "appears at low risk of becoming problematic," her Prenuvo report found. A blood test for lung cancer came back negative, but a CT scan her doctor ordered showed that, sure enough, that lung spot was likely cancer. She eventually had a stage 1 tumor removed, just three months after her Prenuvo scan. Hoeg was in shock. She was a 43-year-old, healthy non-smoker with lung cancer. How could this be? "I'm not out there smoking, asking for lung cancer, I'm not working in a coal mine," she told Business Insider. Since she caught this cancer early, she didn't have to undergo any aggressive radiation or chemotherapy treatments. She tells everyone she can about her experience with Prenuvo. "I have a little bit less lung, I have some scars, but I'm OK, and I'm here, and I'm with my kids, and swimming and running," she said. Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you. What is your job title? (1 of 2) Entry level position Project manager Management Senior management Executive management Student Self-employed Retired Other Continue By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy . Emi Gal, founder of Prenuvo competitor Ezra, recently acquired by Function Health, says this is exactly what full-body scans are meant for. They're helping find cancer that either can't be screened for or won't get picked up on regular screening tests because it's not big enough yet. "My mother passed away from cancer because she found cancer late," Gal told BI. "I've dedicated my career and my life really to helping everyone in the world detect cancer early." The scans can also pick up back and spine problems, aneurysms, liver disease, and cysts. Inevitably, they will also flag many things as worrisome that people don't need to worry about at all, like benign scar tissue or inflammation lingering from a recent illness or injury. The scan can't tell you definitively, "hey, this is trouble." It just shows you when something's there. Are ultrasounds the real untapped medical tool of the future? As the fictional Dr. Cox presciently said on Scrubs, "If you get this scan, the next year of your life is going to be a series of endless tests." Prenuvo says that nearly half of its patients "find something to keep an eye on," but doctors want to know: Are they saving lives? For now, you won't find major medical boards or cancer advocacy organizations recommending full-body MRIs. There isn't the hard evidence they'd need to back up a medical recommendation. "Your end goal is saving years of life, helping people live longer," Dr. Samir Abboud, the chief of emergency radiology at Northwestern Memorial Hospital in Chicago, told BI. If annual scans are overkill, our annual check-ups are often not enough. Independent reviews consistently show that yearly health checks have little to no effect on preventing deadly diseases. Dr. Tim Arling, who runs a concierge medicine practice focused on longevity, says he only occasionally recommends full-body MRIs to his patients. What he's started doing more often is spending a few extra minutes waving a little medical wand over parts of a patient's body as a preliminary scan for trouble. He's using a portable ultrasound machine, the same device doctors use to look at a fetus as it's developing in utero. The technique is common in Japan, where doctors often glide ultrasound wands over a person's thyroid, as an initial screen for cancer. In addition to the thyroid gland, Arling sometimes glides his ultrasound over a patient's liver, kidneys, or aorta, "as a little extension of the physical exam." "If I see something, I'll have a discussion with the patient, we'll decide if we want to do something in real time," he said. The move costs nothing extra to the patient and takes just a few extra minutes. Critically, it also includes the doctor in the discussion from the get-go. Hoeg's stage 1 cancer was graded as a "minor" finding by Prenuvo. If Abboud, who's both a doctor and a friend, hadn't said she should get it looked at ASAP, would she have known to take the finding so seriously? Arling said he went through a "very bizarre three-week period" last year where he ended up flagging a case of early-stage liver cancer, plus another case of early-stage kidney cancer using ultrasounds. "If primary care is trying to catch things earlier, the question comes down to how can we do it in a way that doesn't necessarily add a whole bunch of extra cost or a whole bunch of extra waste?" Maybe "we can start just sort of waving wands over people and getting a little more information," he said. How to decide if you should get a full-body scan: 5 questions to ask For some people, doctors are already in agreement that full-body cancer scans are a good thing. If you have a rare condition called Li-Fraumeni syndrome, which puts you at greater risk of developing all sorts of cancer, annual full-body scans are a go-to, and they're covered by insurance. For everybody else, the jury — a jury full of practicing physicians — is still out. If you're interested in a full-body scan, Dr. Arling recommends weighing a few key factors: 1. What's your family history? You might want to consider a full-body MRI if you've got a family history of cancer. But that scan should be in addition to other recommended cancer screenings you're already doing, Arling said: "paps, mammos, PSAs, colonoscopies, the standard stuff." Another option is a cancer blood test like Galleri. It costs $950. 2. What's your medical anxiety level? If you are anxious about medical care or testing, full-body scans may not be for you. "If you already have that health-anxious person, I'm not super enthusiastic about recommending this test, because they're going to find something," Arling said. 3. What's your level of concern? On the other hand, full-body scans are good at "looking for trouble," Arling said. "If you're really trying to find the thing, not rule out the thing, then the MRI is going to have better data. It has higher sensitivity," he said. It'll be more sensitive than a Galleri test, for example. 4. What's your budget? Is this the best use of a few hundred to a few thousand bucks of your cash? Might you derive more health benefits from putting those dollars into things we know will improve healthy aging, like more exercise, some personal training, better nutrition, or less stress (a nice vacation, perhaps?) "If it gets people being healthy, great, but if it's just a thing that rich people do to flaunt that they're healthier than you, it doesn't quite achieve the goal," Arling said. 5. Is there metal in your body? Finally, full-body MRIs may not be for you if you have metal in your body (sorry). That's because they work by harnessing the power of magnets. There's no harmful radiation involved, but you generally can't wear anything metal, inside or out. (Discuss this with your doctor, though — many surgical implants are designed to be MRI-safe). "A typical three tesla MRI is 60,000 times the strength of the magnetic pull of Earth," Gal said.
Yahoo
15 hours ago
- Yahoo
Why Shares of Peloton Are Surging This Week
Key Points Analysts at UBS upgraded Peloton stock to a buy rating. They see improving trends in the business and are modeling much high EBITDA in fiscal 2026 than consensus Wall Street estimates. 10 stocks we like better than Peloton Interactive › Since the close of trading last Friday, shares of Peloton (NASDAQ: PTON) have surged about 10%, as of 1:24 p.m. ET Thursday. Shares are largely moving higher due to a recent Wall Street analyst report that upgraded the stock. Signs of improvement Peloton, a maker of exercise equipment and content, has seen its stock get absolutely crushed since the main years of the pandemic, as people returned to the gym following the reopening of the economy, among other issues. But now shares are attractively priced, according to UBS analyst Arpine Kocharian, who upgraded the stock to a buy rating and raised the price target from $7 to $11.50. "We see subscription price increases anchoring near-term top line growth, we might also see underlying net subscriber decline stabilizing, outside of price increase driven churn," Kocharian wrote in her research note. "While that inflection in connected fitness subs is not entirely clear to us yet, we are seeing better data trends for Peloton in terms of traffic and active users." Kocharian is modeling $90 million to $100 million in annualized revenue from increases in subscription pricing. The UBS team is also modeling for EBITDA (earnings before interest, taxes, depreciation, and amortization) to come in between $400 million and $450 million in fiscal year 2026, significantly higher than consensus estimates. Attractive valuation At a roughly $2.5 billion market cap, the stock trades at less than 7 times' Kocharian's EBITDA forecast. However, investors should keep in mind that Kocharian is much higher than other analysts on her projection. While Peloton will likely never be the darling it was during the pandemic, the fundamentals do seem to be improving. Peloton is certainly not one of my favorite stocks in the market, but the risk-reward proposition has improved, which is why I think interested investors can start to nibble on the stock. Should you buy stock in Peloton Interactive right now? Before you buy stock in Peloton Interactive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Peloton Interactive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Peloton Interactive. The Motley Fool has a disclosure policy. Why Shares of Peloton Are Surging This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
17 hours ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
